Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2022 –2029 | |
|
|
USD 1.30 Billion |
| USD 5.55 Billion | |
| % | |
|
Global Artificial Intelligence (AI)-based Clinical Trials Market, By Clinical Trial Phase (Phase-I, Phase-II, Phase-III), Application (Oncology, Cardiovascular Diseases, Neurological Diseases or Conditions, Infectious Diseases, Others), End-use (Pharmaceutical Companies, Academia, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
The market for artificial intelligence (AI)-based clinical trials will expand by 21.7 percent over the next five years. The demand for AI-based clinic trial is anticipated to see a solid recovery soon and expand favourably over the long term. In the near future, the Artificial Intelligence (AI)-based clinical trials market business will present rewarding opportunities.
Data Bridge Market Research analyses that the artificial intelligence (AI)-based clinical trials market which was USD 1.3 billion in 2021, would rocket up to USD 5.55 billion by 2029, and is expected to undergo a CAGR of 19.90% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Clinical Trial Phase (Phase-I, Phase-II, Phase-III), Application (Oncology, Cardiovascular Diseases, Neurological Diseases or Conditions, Infectious Diseases, Others), End-use (Pharmaceutical Companies, Academia, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Phesi (India), CONSILX (Singapore), DEEP LENS Inc. (U.S.), Unlearn.AI, Inc. (U.S.), Saama Technologies, LLC (U.S.), Antidote Technologies, Inc. (U.K.), Innoplexus (Germany), Mendel.ai (U.S.), Median Technologies (France), Symphony AI (U.S.), BioAge Labs, Inc. (U.S.), AiCure (U.S.), Halo Health Systems (U.S.)
|
|
Market Opportunities
|
AI can also be used to lessen the bias in medical data
Pharmaceutical companies are heavily incorporating AI-based technologies in clinical trials
|
Market Definition
Artificial intelligence can be used to identify disease, provide healthcare services, and even develop new treatments, while improving clinical trials. The scale and speed of AI are significantly superior to any system that depends just on human activity. In many ways, this will be the biggest problem moving forward because we haven't yet reached an AI level that can run totally autonomously.
Drivers
In recent years, numerous organizations from the public and private sectors have increased their efforts to assist various R&D activities related to therapeutic fields. In the coming years, it is projected that this aspect would open up new growth opportunities in the market for for AI-based clinical trials.
Several companies in the global market for AI-based clinical trials are making significant investments in R&D. The relocation is helping them with the tasks related to new product development and, ultimately, new product launch. The market for providers of AI-based clinical trials is anticipated to grow at a promising rate in the years to come as a result of these factors.
The growing usage of AI-based platforms is driving the market for AI-based clinical trials to enhance the efficiency and efficacy of trials at various stages. Some of the other reasons boosting the market expansion include the supportive activities by the governmental and private sectors for various therapeutic areas. Additionally, the market is being supported by the growing awareness of AI's applications in clinical trials, such as drug trial design, better patient selection, location selection, patient monitoring, etc.
Opportunities
AI can also be used to lessen the bias in medical data. For instance, Genentech and Stanford University worked together to develop an open-source AI system to combat bias in drug studies. Additionally, prominent pharmaceutical companies are heavily incorporating AI-based technologies in clinical trials, which is helping the market growth. This is owing to the trend of moving away from old procedures and toward technology-based approaches.
Restraints/Challenges
On the other hand, the high cost associated with drug development and distribution will obstruct the market's growth rate.
This Artificial Intelligence (AI)-based clinical trials market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Artificial Intelligence (AI)-based clinical trials market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
The COVID-19 epidemic contributed to an increase in the use of AI-based technology. One reason for the rise in the use of AI-based drug research and drug trial solutions is the increasing adoption of technologically enhanced drug discovery and development solutions, as well as the analysis of recruited patient data. To improve clinical outcomes and reduce the cost and time needed for drug trials, pharmaceutical companies, CROs, and academics have switched their attention away from the conventional drug development process and toward the AI-based solution. Decentralized drug trials also saw a result of the COVID-19 trial suspensions, which led several major players to focus on gathering patient data.
The Artificial Intelligence (AI)-based clinical trials market is segmented on the basis of clinical trial phase, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Clinical Trial Phase
Application
End-user
The Artificial Intelligence (AI)-based clinical trials market is analysed and market size insights and trends are provided by country, clinical trial phase, application and end-user as referenced above.
The countries covered in the Artificial Intelligence (AI)-based clinical trials market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the Artificial Intelligence (AI)-based clinical trials market. This growth can be attributed to many factors including surge in the number of clinical trials carried out in the region.
Asia-Pacific is expected to grow exhibit lucrative growth over the forecast period due to the rising penetration of AI-based tools and favourable government initiatives for the adoption of AI in different healthcare fields.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The Artificial Intelligence (AI)-based clinical trials market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for AI-based clinical trials market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Artificial Intelligence (AI)-based clinical trials market. The data is available for historic period 2010-2020.
The Artificial Intelligence (AI)-based clinical trials market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Artificial Intelligence (AI)-based clinical trials market.
Some of the major players operating in the Artificial Intelligence (AI)-based clinical trials market are:
SKU-
1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ARTIFICIAL INTELLIGENCE (AI)-BASED CLINICAL TRIALS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2. MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL ARTIFICIAL INTELLIGENCE (AI)-BASED CLINICAL TRIALS MARKET
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET GUIDE
2.2.4 COMAPANY MARKET SHARE ANALYSIS
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 STANDARDS OF MEASUREMENT
2.2.8 VENDOR SHARE ANALYSIS
2.2.9 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.10 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ARTIFICIAL INTELLIGENCE (AI)-BASED CLINICAL TRIALS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3. MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6. INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7. INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8. COST ANALYSIS BREAKDOWN
9. TECHNONLOGY ROADMAP
10. INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11. REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12. REIMBURSEMENT FRAMEWORK
13. OPPUTUNITY MAP ANALYSIS
14. VALUE CHAIN ANALYSIS
15. HEALTHCARE ECONOMY
15.1 HEALTHCARE EXPENDITURE
15.2 CAPITAL EXPENDITURE
15.3 CAPEX TRENDS
15.4 CAPEX ALLOCATION
15.5 FUNDING SOURCES
15.6 INDUSTRY BENCHMARKS
15.7 GDP RATION IN OVERALL GDP
15.8 HEALTHCARE SYSTEM STRUCTURE
15.9 GOVERNMENT POLICIES
15.10 ECONOMIC DEVELOPMENT
16. GLOBAL ARTIFICIAL INTELLIGENCE (AI)-BASED CLINICAL TRIALS MARKET, BY OFFERING
16.1 OVERVIEW
16.2 SOFTWARE
16.2.1 BY DEPLOYMENT MODE
16.2.1.1. CLOUD
16.2.1.2. ON-PREMISES
16.2.2 BY TYPE
16.2.2.1. STANDALONE
16.2.2.2. INTEGRATED
16.3 SERVICES
16.3.1 DEPLOYMENT & INTEGRATION
16.3.2 SUPPORT & MAINTENANCE
17. GLOBAL ARTIFICIAL INTELLIGENCE (AI)-BASED CLINICAL TRIALS MARKET, BY TECHNOLOGY
17.1 OVERVIEW
17.2 MACHINE LEARNING
17.2.1 DEEP LEARNING
17.2.1.1. CONVOLUTIONAL NEURAL NETWORK (CNN)
17.2.1.2. RECURRENT NEURAL NETWORK (RNN)
17.2.1.3. GENERATIVE ADVERSARIAL NETWORKS (GAN)
17.2.2 SUPERVISED LEARNING
17.2.3 REINFORCEMENT LEARNING
17.2.4 UNSUPERVISED LEARNING
17.3 NATURAL LANGUAGE PROCESSING
17.3.1 IVR
17.3.2 OCR
17.3.3 PATTERN & IMAGE RECOGNITION
17.3.4 AUTO CODING
17.3.5 CLASSIFICATION & CATEGORIZATION
17.3.6 TEXT ANALYTICS
17.3.7 SPEECH ANALYTICS
17.4 CONTEXT-AWARENESS COMPUTING
17.4.1 DEVICE CONTEXT
17.4.2 USER CONTEXT
17.4.3 PHYSICAL CONTEXT
17.5 COMPUTER VISION
17.6 OTHERS
18. GLOBAL ARTIFICIAL INTELLIGENCE (AI)-BASED CLINICAL TRIALS MARKET, BY PHASE
18.1 OVERVIEW
18.2 PHASE I
18.3 PHASE II
18.4 PHASE III
18.5 PHASE IV
19. GLOBAL ARTIFICIAL INTELLIGENCE (AI)-BASED CLINICAL TRIALS MARKET, BY TRIAL DESIGN
19.1 OVERVIEW
19.2 INTERVENTIONAL
19.3 TREATMENT
19.4 OBSERVATIONAL
19.5 EXPANDED ACCESS
20. GLOBAL ARTIFICIAL INTELLIGENCE (AI)-BASED CLINICAL TRIALS MARKET, BY APPLICATION
20.1 OVERVIEW
20.2 ONCOLOGY
20.3 NEUROLOGY DISEASES AND CONDITIONS
20.4 CARDIOVASCULAR DISEASES
20.5 METABOLIC DISEASES
20.6 INFECTIOUS DISEASES
20.7 IMMUNOLOGY DISEASES
20.8 OTHERS
21. GLOBAL ARTIFICIAL INTELLIGENCE (AI)-BASED CLINICAL TRIALS MARKET, BY END USER
21.1 OVERVIEW
21.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
21.2.1 BY OFFERING
21.2.1.1. SOFTWARE
21.2.1.2. SERVICES
21.3 CONTRACT RESEARCH ORGANIZATIONS
21.3.1 BY OFFERING
21.3.1.1. SOFTWARE
21.3.1.2. SERVICES
21.4 RESEARCH CENTRES AND ACADEMIC INSTITUTES
21.4.1 BY OFFERING
21.4.1.1. SOFTWARE
21.4.1.2. SERVICES
21.5 OTHERS
22. GLOBAL ARTIFICIAL INTELLIGENCE (AI)-BASED CLINICAL TRIALS MARKET, BY GEOGRAPHY
22.1 GLOBAL ARTIFICIAL INTELLIGENCE (AI)-BASED CLINICAL TRIALS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
22.1.1 NORTH AMERICA
22.1.1.1. U.S.
22.1.1.2. CANADA
22.1.1.3. MEXICO
22.1.2 EUROPE
22.1.2.1. GERMANY
22.1.2.2. FRANCE
22.1.2.3. U.K.
22.1.2.4. ITALY
22.1.2.5. SPAIN
22.1.2.6. RUSSIA
22.1.2.7. TURKEY
22.1.2.8. BELGIUM
22.1.2.9. NETHERLANDS
22.1.2.10. NORWAY
22.1.2.11. FINLAND
22.1.2.12. SWITZERLAND
22.1.2.13. DENMARK
22.1.2.14. SWEDEN
22.1.2.15. POLAND
22.1.2.16. REST OF EUROPE
22.1.3 ASIA PACIFIC
22.1.3.1. JAPAN
22.1.3.2. CHINA
22.1.3.3. SOUTH KOREA
22.1.3.4. INDIA
22.1.3.5. AUSTRALIA
22.1.3.6. NEW ZEALAND
22.1.3.7. SINGAPORE
22.1.3.8. THAILAND
22.1.3.9. MALAYSIA
22.1.3.10. INDONESIA
22.1.3.11. PHILIPPINES
22.1.3.12. TAIWAN
22.1.3.13. VIETNAM
22.1.3.14. REST OF ASIA PACIFIC
22.1.4 SOUTH AMERICA
22.1.4.1. BRAZIL
22.1.4.2. ARGENTINA
22.1.4.3. REST OF SOUTH AMERICA
22.1.5 MIDDLE EAST AND AFRICA
22.1.5.1. SOUTH AFRICA
22.1.5.2. EGYPT
22.1.5.3. SAUDI ARABIA
22.1.5.4. U.A.E
22.1.5.5. OMAN
22.1.5.6. BAHRAIN
22.1.5.7. ISRAEL
22.1.5.8. KUWAIT
22.1.5.9. QATAR
22.1.5.10. REST OF MIDDLE EAST AND AFRICA
22.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
23. GLOBAL ARTIFICIAL INTELLIGENCE (AI)-BASED CLINICAL TRIALS MARKET,COMPANY LANDSCAPE
23.1 COMPANY SHARE ANALYSIS: GLOBAL
23.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
23.3 COMPANY SHARE ANALYSIS: EUROPE
23.4 COMPANY SHARE ANALYSIS: ASIA PACIFIC
23.5 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
23.6 MERGERS & ACQUISITIONS
23.7 NEW PRODUCT DEVELOPMENT AND APPROVALS
23.8 EXPANSIONS
23.9 REGULATORY CHANGES
23.10 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
24. GLOBAL ARTIFICIAL INTELLIGENCE (AI)-BASED CLINICAL TRIALS MARKET, SWOT & DBMR ANALYSIS
25. GLOBAL ARTIFICIAL INTELLIGENCE (AI)-BASED CLINICAL TRIALS MARKET, COMPANY PROFILE
25.1 PHESI
25.1.1 COMPANY SNAPSHOT
25.1.2 REVENUE ANALYSIS
25.1.3 GEOGRAPHIC PRESENCE
25.1.4 PRODUCT PORTFOLIO
25.1.5 RECENT DEVELOPMENT
25.2 MEDIDATA (A PART OF DASSAULT SYSTÈMES)
25.2.1 COMPANY SNAPSHOT
25.2.2 REVENUE ANALYSIS
25.2.3 GEOGRAPHIC PRESENCE
25.2.4 PRODUCT PORTFOLIO
25.2.5 RECENT DEVELOPMENT
25.3 IQVIA INC
25.3.1 COMPANY SNAPSHOT
25.3.2 REVENUE ANALYSIS
25.3.3 GEOGRAPHIC PRESENCE
25.3.4 PRODUCT PORTFOLIO
25.3.5 RECENT DEVELOPMENT
25.4 RENALYTIX
25.4.1 COMPANY SNAPSHOT
25.4.2 REVENUE ANALYSIS
25.4.3 GEOGRAPHIC PRESENCE
25.4.4 PRODUCT PORTFOLIO
25.4.5 RECENT DEVELOPMENT
25.5 PARADIGM HEALTH, INC (DEEP LENS)
25.5.1 COMPANY SNAPSHOT
25.5.2 REVENUE ANALYSIS
25.5.3 GEOGRAPHIC PRESENCE
25.5.4 PRODUCT PORTFOLIO
25.5.5 RECENT DEVELOPMENT
25.6 UNLEARN.AI, INC.
25.6.1 COMPANY SNAPSHOT
25.6.2 REVENUE ANALYSIS
25.6.3 GEOGRAPHIC PRESENCE
25.6.4 PRODUCT PORTFOLIO
25.6.5 RECENT DEVELOPMENT
25.7 SAAMA TECHNOLOGIES, INC.
25.7.1 COMPANY SNAPSHOT
25.7.2 REVENUE ANALYSIS
25.7.3 GEOGRAPHIC PRESENCE
25.7.4 PRODUCT PORTFOLIO
25.7.5 RECENT DEVELOPMENT
25.8 INNOPLEXUS
25.8.1 COMPANY SNAPSHOT
25.8.2 REVENUE ANALYSIS
25.8.3 GEOGRAPHIC PRESENCE
25.8.4 PRODUCT PORTFOLIO
25.8.5 RECENT DEVELOPMENT
25.9 MENDEL.AI
25.9.1 COMPANY SNAPSHOT
25.9.2 REVENUE ANALYSIS
25.9.3 GEOGRAPHIC PRESENCE
25.9.4 PRODUCT PORTFOLIO
25.9.5 RECENT DEVELOPMENT
25.10 MEDIAN TECHNOLOGIES
25.10.1 COMPANY SNAPSHOT
25.10.2 REVENUE ANALYSIS
25.10.3 GEOGRAPHIC PRESENCE
25.10.4 PRODUCT PORTFOLIO
25.10.5 RECENT DEVELOPMENT
25.11 IBM
25.11.1 COMPANY SNAPSHOT
25.11.2 REVENUE ANALYSIS
25.11.3 GEOGRAPHIC PRESENCE
25.11.4 PRODUCT PORTFOLIO
25.11.5 RECENT DEVELOPMENT
25.12 EXSCIENTIA
25.12.1 COMPANY SNAPSHOT
25.12.2 REVENUE ANALYSIS
25.12.3 GEOGRAPHIC PRESENCE
25.12.4 PRODUCT PORTFOLIO
25.12.5 RECENT DEVELOPMENT
25.13 PAREXEL INTERNATIONAL CORPORATION (PARTNER WITH PARTEX )
25.13.1 COMPANY SNAPSHOT
25.13.2 REVENUE ANALYSIS
25.13.3 GEOGRAPHIC PRESENCE
25.13.4 PRODUCT PORTFOLIO
25.13.5 RECENT DEVELOPMENT
25.14 INSILICO MEDICINE
25.14.1 COMPANY SNAPSHOT
25.14.2 REVENUE ANALYSIS
25.14.3 GEOGRAPHIC PRESENCE
25.14.4 PRODUCT PORTFOLIO
25.14.5 RECENT DEVELOPMENT
25.15 INTEL CORPORATION
25.15.1 COMPANY SNAPSHOT
25.15.2 REVENUE ANALYSIS
25.15.3 GEOGRAPHIC PRESENCE
25.15.4 PRODUCT PORTFOLIO
25.15.5 RECENT DEVELOPMENT
25.16 AICURE
25.16.1 COMPANY SNAPSHOT
25.16.2 REVENUE ANALYSIS
25.16.3 GEOGRAPHIC PRESENCE
25.16.4 PRODUCT PORTFOLIO
25.16.5 RECENT DEVELOPMENT
25.17 CONCERTAI
25.17.1 COMPANY SNAPSHOT
25.17.2 REVENUE ANALYSIS
25.17.3 GEOGRAPHIC PRESENCE
25.17.4 PRODUCT PORTFOLIO
25.17.5 RECENT DEVELOPMENT
25.18 NURITAS LTD.
25.18.1 COMPANY SNAPSHOT
25.18.2 REVENUE ANALYSIS
25.18.3 GEOGRAPHIC PRESENCE
25.18.4 PRODUCT PORTFOLIO
25.18.5 RECENT DEVELOPMENT
25.19 BULLFROG AI HOLDINGS, INC.
25.19.1 COMPANY SNAPSHOT
25.19.2 REVENUE ANALYSIS
25.19.3 GEOGRAPHIC PRESENCE
25.19.4 PRODUCT PORTFOLIO
25.19.5 RECENT DEVELOPMENT
25.20 VIZ.AI
25.20.1 COMPANY SNAPSHOT
25.20.2 REVENUE ANALYSIS
25.20.3 GEOGRAPHIC PRESENCE
25.20.4 PRODUCT PORTFOLIO
25.20.5 RECENT DEVELOPMENT
25.21 TRINETX, LLC
25.21.1 COMPANY SNAPSHOT
25.21.2 REVENUE ANALYSIS
25.21.3 GEOGRAPHIC PRESENCE
25.21.4 PRODUCT PORTFOLIO
25.21.5 RECENT DEVELOPMENT
25.22 CLINITHINK
25.22.1 COMPANY SNAPSHOT
25.22.2 REVENUE ANALYSIS
25.22.3 GEOGRAPHIC PRESENCE
25.22.4 PRODUCT PORTFOLIO
25.22.5 RECENT DEVELOPMENT
25.23 VEEVA SYSTEMS
25.23.1 COMPANY SNAPSHOT
25.23.2 REVENUE ANALYSIS
25.23.3 GEOGRAPHIC PRESENCE
25.23.4 PRODUCT PORTFOLIO
25.23.5 RECENT DEVELOPMENT
25.24 CLARIO
25.24.1 COMPANY SNAPSHOT
25.24.2 REVENUE ANALYSIS
25.24.3 GEOGRAPHIC PRESENCE
25.24.4 PRODUCT PORTFOLIO
25.24.5 RECENT DEVELOPMENT
25.25 NFERENCE, INC
25.25.1 COMPANY SNAPSHOT
25.25.2 REVENUE ANALYSIS
25.25.3 GEOGRAPHIC PRESENCE
25.25.4 PRODUCT PORTFOLIO
25.25.5 RECENT DEVELOPMENT
25.26 TRIALS.AI
25.26.1 COMPANY SNAPSHOT
25.26.2 REVENUE ANALYSIS
25.26.3 GEOGRAPHIC PRESENCE
25.26.4 PRODUCT PORTFOLIO
25.26.5 RECENT DEVELOPMENT
25.27 RISKLICK.CH
25.27.1 COMPANY SNAPSHOT
25.27.2 REVENUE ANALYSIS
25.27.3 GEOGRAPHIC PRESENCE
25.27.4 PRODUCT PORTFOLIO
25.27.5 RECENT DEVELOPMENT
25.28 UNLEARN.AI, INC
25.28.1 COMPANY SNAPSHOT
25.28.2 REVENUE ANALYSIS
25.28.3 GEOGRAPHIC PRESENCE
25.28.4 PRODUCT PORTFOLIO
25.28.5 RECENT DEVELOPMENT
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
26. CONCLUSION
27. QUESTIONNAIRE
28. RELATED REPORTS
29. ABOUT DATA BRIDGE MARKET RESEARCH
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.